Nebenwirkungen · Eyluxvi
Eyluxvi 40 mg/mL solution for injection in a vial. · Abschnitt 4.8 · PDF-Seite 8–9
HOS-152373 · Präparat HOS-100741
Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. 8 A low incidence rate of arterial thromboembolic events was observed in the aflibercept clinical trials in patients with AMD, DME, RVO and myopic CNV. Across indications no notable difference between the groups treated with aflibercept and the respective comparator groups were observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T12:42:00Z · SHA-256 26254e6a9182cfe8d723c0f697c4b6a43be2ec8912ddfeeb8ba0390b7a0d1d25 · Passage 828bf4c8a202877b43e104cc63fd9c83d41e8d7daeb1711931a5ab55558be015 · Zeichen 4945–5558 im Abschnitt